{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:45:51Z","timestamp":1778946351183,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002661","name":"FNRS","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.jcv.2020.104547","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T12:01:30Z","timestamp":1594209690000},"page":"104547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Drug resistance in HIV-infected children living in rural South Africa: Implications of an antiretroviral therapy initiated during the first year of life"],"prefix":"10.1016","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4453-1017","authenticated-orcid":false,"given":"Jean-Christophe","family":"Beghin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Ruelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Goubau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitri","family":"Van der Linden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2020.104547_bib0005","unstructured":"World Health Organization. Number of children (15 years) receiving ART globally, and by WHO region, 2000\u20132015. (http:\/\/www.who.int\/hiv\/data\/pedartregions2016.png?ua=1)."},{"issue":"1","key":"10.1016\/j.jcv.2020.104547_bib0010","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/QAI.0b013e3181b9869f","article-title":"Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era","volume":"53","author":"Brady","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"3","key":"10.1016\/j.jcv.2020.104547_bib0015","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/QAI.0b013e31827b4ac8","article-title":"Long-term virologic response and genotypic resistance mutations in HIV-1 infected Kenyan children on combination antiretroviral therapy","volume":"62","author":"Wamalwa","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jcv.2020.104547_bib0020","article-title":"Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age","volume":"5","author":"Penazzato","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.jcv.2020.104547_bib0025","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/QAI.0b013e3182060610","article-title":"Virologic failure and second-line antiretroviral therapy in children in South Africa - the IeDEA Southern Africa Collaboration","volume":"56","author":"Davies","year":"2011","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"2","key":"10.1016\/j.jcv.2020.104547_bib0030","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/INF.0000000000000544","article-title":"Virologic failure among children taking lopinavir\/ritonavir-containing first-line antiretroviral therapy in South Africa","volume":"34","author":"Meyers","year":"2015","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.jcv.2020.104547_bib0035","doi-asserted-by":"crossref","first-page":"690","DOI":"10.4172\/2155-6113.1000690","article-title":"Virological and immunological long-term outcome of human immunodeficiency virus-1 infected children treated before one year and after two years of age in a resource-limited setting of South Africa","volume":"8","author":"Beghin","year":"2017","journal-title":"J. AIDS Clin. Res."},{"key":"10.1016\/j.jcv.2020.104547_bib0040","series-title":"National Consolidated Guidelines for the Prevention of Mother to Child Transmission of HIV (PMTCT) and the Management of HIV in Children, Adolescent and Adults","year":"2015"},{"key":"10.1016\/j.jcv.2020.104547_bib0045","unstructured":"WHO Library Cataloguing-in-Publication Data. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach \u2013 2nd ed. June 2016. Available from: http:\/\/www.who.int\/hiv\/pub\/arv\/arv-2016\/en\/."},{"key":"10.1016\/j.jcv.2020.104547_bib0050","series-title":"Global Evaluation Services. Systematic Literature Review Report: Which Interventions Enhance Adherence to ART for People Living with HIV?","author":"Mills","year":"2015"},{"issue":"2","key":"10.1016\/j.jcv.2020.104547_bib0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116144","article-title":"Factors associated with virological failure and suppression after enhanced adherence counselling, in children, adolescents and adults on antiretroviral therapy for HIV in Swaziland","volume":"10","author":"Jobanputra","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jcv.2020.104547_bib0060","unstructured":"Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. (http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/pediatricguidelines.pdf)."},{"key":"10.1016\/j.jcv.2020.104547_bib0065","unstructured":"Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in pr\u00e9paration for adult life."},{"issue":"4","key":"10.1016\/j.jcv.2020.104547_bib0070","first-page":"221","article-title":"Implementing HIV-1 genotypic resistance testing in antiretroviral therapy programs in Africa: needs, opportunities, and challenges","volume":"15","author":"Lessells","year":"2013","journal-title":"AIDS Rev."},{"issue":"11","key":"10.1016\/j.jcv.2020.104547_bib0075","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1089\/aid.2008.0180","article-title":"HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy","volume":"11","author":"Pillay","year":"2008","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"12","key":"10.1016\/j.jcv.2020.104547_bib0080","first-page":"1123","article-title":"Emergence of drug resistance in HIV-1 subtype C infected children failing the South African National Antiretroviral roll-out program","volume":"11","author":"Wallis","year":"2009","journal-title":"Paeiatric I nfectious Dis J."},{"issue":"12","key":"10.1016\/j.jcv.2020.104547_bib0085","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/INF.0b013e3181af829d","article-title":"Protease inhibitor resistance in South African children with virologic failure","volume":"11","author":"van Zyl","year":"2009","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.jcv.2020.104547_bib0090","first-page":"1497","article-title":"Pharmacotherapy of HIV-1 infection: focus on CCR5 antagonist maraviroc","volume":"11","author":"Latinovic","year":"2009","journal-title":"Clin. Med. Ther."},{"issue":"1","key":"10.1016\/j.jcv.2020.104547_bib0095","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/INF.0b013e3181ed2af3","article-title":"Long-term outcome of children receiving antiretroviral treatment in Rural South Africa","volume":"11","author":"Barth","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"9","key":"10.1016\/j.jcv.2020.104547_bib0100","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1089\/aid.2010.0205","article-title":"Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of Age initiating protease inhibitor-based therapy in South Africa","volume":"11","author":"Taylor","year":"2011","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"4","key":"10.1016\/j.jcv.2020.104547_bib0105","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1089\/aid.2011.0106","article-title":"Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in South Africa","volume":"11","author":"Green","year":"2012","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"1","key":"10.1016\/j.jcv.2020.104547_bib0110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1742-6405-11-3","article-title":"Drug resistance in children at virological failure in a rural KwaZulu-Natal, South Africa, cohort","volume":"11","author":"Pillay","year":"2014","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/j.jcv.2020.104547_bib0115","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/tropej\/fmr053","article-title":"Feasibility and effectiveness of early initiation of combination antiretroviral therapy in HIV- infected infants in a government clinic of Kwazulu-Natal, South Africa","volume":"58","author":"Purchase","year":"2012","journal-title":"J. Trop. Pediatr."},{"key":"10.1016\/j.jcv.2020.104547_bib0120","series-title":"AIDS Epidemic Update 2010","author":"World Health Organization","year":"2010"},{"key":"10.1016\/j.jcv.2020.104547_bib0125","series-title":"Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach","author":"World Health Organization","year":"2013"},{"key":"10.1016\/j.jcv.2020.104547_bib0130","series-title":"Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.jcv.2020.104547_bib0135","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa0800971","article-title":"Early antiretroviral therapy and mortality among HIV-infected infants","volume":"359","author":"Violari","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2020.104547_bib0140","first-page":"5","article-title":"Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age","volume":"22","author":"Penazzato","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jcv.2020.104547_bib0145","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/INF.0b013e31827fb19d","article-title":"Cognitive function and neurodevelopmental outcomes in HIV- infected Children older than 1 year of age randomized to early versus deferred antiretroviral therapy: the PREDICT neurodevelopmental study","volume":"32","author":"Puthanakit","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.jcv.2020.104547_bib0150","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jpeds.2012.11.025","article-title":"Initiation of antiretroviral therapy before 6 months of age is associated with faster growth recovery in South African children perinatally infected with human immunodeficiency virus","volume":"162","author":"Shiau","year":"2013","journal-title":"J. Pediatr."},{"key":"10.1016\/j.jcv.2020.104547_bib0155","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S1473-3099(08)70180-4","article-title":"Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa","volume":"8","author":"Sutcliffe","year":"2008","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jcv.2020.104547_bib0160","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2431-7-13","article-title":"Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa","volume":"7","author":"Reddi","year":"2007","journal-title":"BMC Pediatr."},{"key":"10.1016\/j.jcv.2020.104547_bib0165","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/j.1651-2227.2003.tb00822.x","article-title":"Adherence to antiretroviral therapy and its determinants in children with human immunodeficiency virus infection: a multicentre, national study","volume":"92","author":"Giacomet","year":"2003","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.jcv.2020.104547_bib0170","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1089\/apc.2006.20.429","article-title":"Caregiver psychosocial characteristics and children\u2019s adherence to antiretroviral therapy","volume":"20","author":"Marhefka","year":"2006","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.jcv.2020.104547_bib0175","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1097\/00002030-200409240-00006","article-title":"Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, C\u00f4te d\u2019Ivoire","volume":"18","author":"Elenga","year":"2004","journal-title":"AIDS."},{"issue":"4","key":"10.1016\/j.jcv.2020.104547_bib0180","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11904-009-0026-8","article-title":"Pediatric adherence to HIV antiretroviral therapy","volume":"6","author":"Haberer","year":"2009","journal-title":"Curr. HIV\/AIDS Rep."},{"issue":"5","key":"10.1016\/j.jcv.2020.104547_bib0185","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.bjid.2016.05.009","article-title":"Adherence to antiretroviral therapy of Brazilian HIV-infected children and their caregivers","volume":"20","author":"Ricci","year":"2016","journal-title":"Braz. J. Infect. Dis."},{"key":"10.1016\/j.jcv.2020.104547_bib0190","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1471-2431-14-114","article-title":"Caregiver-reported adherence to antiretroviral therapy among HIV infected children in Mekelle, Ethiopia","volume":"14","author":"Eticha","year":"2014","journal-title":". BMC Pediatr."},{"key":"10.1016\/j.jcv.2020.104547_bib0195","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/bmj.332.7551.1183","article-title":"Collaborative HIV Paediatric Study Steering Committee Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997\u20132005: cohort study","volume":"332","author":"Menson","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.jcv.2020.104547_bib0200","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1749-6632.2000.tb05504.x","article-title":"Factors with a negative influence on compliance to antiretroviral therapies","volume":"918","author":"Cupsa","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"6","key":"10.1016\/j.jcv.2020.104547_bib0205","doi-asserted-by":"crossref","first-page":"689","DOI":"10.5588\/ijtld.13.0492","article-title":"Double-dose lopinavir-ritonavir in combination with rifampicin-based anti-tuberculosis treatment in South Africa","volume":"18","author":"Sunpath","year":"2014","journal-title":"Int. J. Tuberc. Lung Dis."},{"issue":"2","key":"10.1016\/j.jcv.2020.104547_bib0210","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1542\/peds.2013-3225","article-title":"Pediatric drug formulations: a review of challenges and progress","volume":"134","author":"Rademaker","year":"2014","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.jcv.2020.104547_bib0215","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1179\/1465328111Y.0000000025","article-title":"Adherence to tablet and liquid formulations of antiretroviral medication for paediatric HIV treatment at an urban clinic in Uganda","volume":"31","author":"Bagenda","year":"2011","journal-title":"Ann. Trop. Paediatr."},{"issue":"Suppl. 1","key":"10.1016\/j.jcv.2020.104547_bib0220","first-page":"S2","article-title":"Addressing the challenges of adherence","volume":"29","author":"Bartlett","year":"2002","journal-title":"JAIDS"},{"issue":"Suppl. 2","key":"10.1016\/j.jcv.2020.104547_bib0225","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1093\/infdis\/jit115","article-title":"Development of antiretroviral resistance in children with HIV in low- and middle-income countries","volume":"207","author":"Fitzgerald","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jcv.2020.104547_bib0230","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1473-3099(11)70141-4","article-title":"HIV-1- resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review","volume":"11","author":"Sigaloff","year":"2011","journal-title":"Lancet Infect. Dis."},{"issue":"10","key":"10.1016\/j.jcv.2020.104547_bib0235","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/cid\/civ109","article-title":"Lopinavir\/ritonavir monotherapy as second-line antiretroviral treatment in resource-limited settings: week 104 analysis of AIDS clinical trials group (ACTG) A5230","volume":"60","author":"Kumarasamy","year":"2015","journal-title":"Clin. Infect. Dis."},{"issue":"11","key":"10.1016\/j.jcv.2020.104547_bib0240","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1097\/QAD.0b013e328353b066","article-title":"Lopinavir\/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings","volume":"26","author":"Bartlett","year":"2012","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.jcv.2020.104547_bib0245","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jac\/dkw463","article-title":"Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-analysis","volume":"72","author":"Sigaloff","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2020.104547_bib0250","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/QAI.0b013e318050d652","article-title":"Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, C\u00f4te d\u2019Ivoire","volume":"45","author":"Martinson","year":"2007","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"10","key":"10.1016\/j.jcv.2020.104547_bib0255","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1001\/jama.2010.1278","article-title":"Re-use of nevirapine in exposed HIV-Infected children after viral suppression with a protease inhibitor-based treatment regimen: a randomized controlled trial","volume":"304","author":"Coovadia","year":"2010","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.jcv.2020.104547_bib0260","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1473-3099(12)70051-8","article-title":"Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial","volume":"12","author":"Kuhn","year":"2012","journal-title":"Lancet Infect. Dis."},{"issue":"8","key":"10.1016\/j.jcv.2020.104547_bib0265","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/QAD.0000000000001446","article-title":"Persistence of HIV drug resistance among South African children given nevirapine to prevent mother-to-child-transmission","volume":"31","author":"Kanthula","year":"2017","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.jcv.2020.104547_bib0270","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12916-017-0842-4","article-title":"Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and C\u00f4te d\u2019Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial","volume":"15","author":"Dahourou","year":"2017","journal-title":"BMC Med."},{"key":"10.1016\/j.jcv.2020.104547_bib0275","series-title":"HIV Drug Resistance Report 2017","year":"2017"},{"issue":"8","key":"10.1016\/j.jcv.2020.104547_bib0280","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1128\/AAC.00315-13","article-title":"Lopinavir plasma concentrations and virological outcome with lopinavir-ritonavir monotherapy in HIV-1-infected patients","volume":"57","author":"Lopez-Cortes","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.jcv.2020.104547_bib0285","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1473-3099(17)30630-8","article-title":"Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial","volume":"18","author":"Hakim","year":"2018","journal-title":"Lancet Infect. Dis."},{"issue":"3","key":"10.1016\/j.jcv.2020.104547_bib0290","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/QAD.0b013e3282f3f16d","article-title":"Lopinavir\/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients","volume":"22","author":"Delfraissy","year":"2008","journal-title":"AIDS"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653220302894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653220302894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T03:12:23Z","timestamp":1761361943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653220302894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":58,"alternative-id":["S1386653220302894"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2020.104547","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug resistance in HIV-infected children living in rural South Africa: Implications of an antiretroviral therapy initiated during the first year of life","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2020.104547","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104547"}}